Apimeds Pharmaceuticals US, Inc (AMEX: APUS) Stock Competitors & Peer Comparison

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, VRTX has a market cap of 132.6B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while VRTX trades at $522.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas VRTX's P/E ratio is 27.45. In terms of profitability, APUS's ROE is -0.59%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, APUS is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check VRTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, REGN has a market cap of 82B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while REGN trades at $796.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas REGN's P/E ratio is 17.45. In terms of profitability, APUS's ROE is -0.59%, compared to REGN's ROE of +0.14%. Regarding short-term risk, APUS is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check REGN's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, MRNA has a market cap of 77.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while MRNA trades at $194.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas MRNA's P/E ratio is -23.90. In terms of profitability, APUS's ROE is -0.59%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, APUS is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check MRNA's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas VRNA's P/E ratio is -102.80. In terms of profitability, APUS's ROE is -0.59%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, APUS is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check VRNA's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ARGX has a market cap of 59.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ARGX trades at $962.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ARGX's P/E ratio is 34.69. In terms of profitability, APUS's ROE is -0.59%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, APUS is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ARGX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas SGEN's P/E ratio is -57.19. In terms of profitability, APUS's ROE is -0.59%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, APUS is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SGEN's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, RVMD has a market cap of 42.5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while RVMD trades at $199.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas RVMD's P/E ratio is -22.66. In terms of profitability, APUS's ROE is -0.59%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, APUS is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RVMD's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, RVMDW has a market cap of 42.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while RVMDW trades at $10.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas RVMDW's P/E ratio is -1.22. In terms of profitability, APUS's ROE is -0.59%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, APUS is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RVMDW's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ONC has a market cap of 38.5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ONC trades at $359.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ONC's P/E ratio is 63.38. In terms of profitability, APUS's ROE is -0.59%, compared to ONC's ROE of +0.14%. Regarding short-term risk, APUS is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ONC's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ALNY has a market cap of 33.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ALNY trades at $249.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ALNY's P/E ratio is 44.97. In terms of profitability, APUS's ROE is -0.59%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, APUS is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ALNY's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, INSM has a market cap of 26.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while INSM trades at $121.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas INSM's P/E ratio is -29.57. In terms of profitability, APUS's ROE is -0.59%, compared to INSM's ROE of -1.11%. Regarding short-term risk, APUS is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check INSM's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ROIV has a market cap of 26.1B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ROIV trades at $36.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ROIV's P/E ratio is -34.37. In terms of profitability, APUS's ROE is -0.59%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, APUS is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ROIV's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, INCY has a market cap of 25.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while INCY trades at $124.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas INCY's P/E ratio is 16.73. In terms of profitability, APUS's ROE is -0.59%, compared to INCY's ROE of +0.30%. Regarding short-term risk, APUS is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for APUS.Check INCY's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, BNTX has a market cap of 24.9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while BNTX trades at $99.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas BNTX's P/E ratio is -12.87. In terms of profitability, APUS's ROE is -0.59%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, APUS is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BNTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, GMAB has a market cap of 21.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while GMAB trades at $34.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas GMAB's P/E ratio is 26.25. In terms of profitability, APUS's ROE is -0.59%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, APUS is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for APUS.Check GMAB's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas BGNE's P/E ratio is -22.55. In terms of profitability, APUS's ROE is -0.59%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, APUS is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BGNE's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, UTHR has a market cap of 20B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while UTHR trades at $472.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas UTHR's P/E ratio is 16.89. In terms of profitability, APUS's ROE is -0.59%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, APUS is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for APUS.Check UTHR's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, APUS's ROE is -0.59%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, APUS is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check DNA-WT's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while JAZZ trades at $236.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas JAZZ's P/E ratio is 8.81. In terms of profitability, APUS's ROE is -0.59%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, APUS is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for APUS.Check JAZZ's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, EXEL has a market cap of 14.6B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while EXEL trades at $57.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas EXEL's P/E ratio is 16.56. In terms of profitability, APUS's ROE is -0.59%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, APUS is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check EXEL's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ASND has a market cap of 14.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ASND trades at $230.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ASND's P/E ratio is -95.33. In terms of profitability, APUS's ROE is -0.59%, compared to ASND's ROE of +1.90%. Regarding short-term risk, APUS is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ASND's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, NBIX has a market cap of 14B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while NBIX trades at $138.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas NBIX's P/E ratio is 20.08. In terms of profitability, APUS's ROE is -0.59%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, APUS is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check NBIX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, HALO has a market cap of 13.7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while HALO trades at $115.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas HALO's P/E ratio is 21.50. In terms of profitability, APUS's ROE is -0.59%, compared to HALO's ROE of +1.81%. Regarding short-term risk, APUS is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for APUS.Check HALO's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, SMMT has a market cap of 13.1B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while SMMT trades at $16.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas SMMT's P/E ratio is -14.62. In terms of profitability, APUS's ROE is -0.59%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, APUS is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SMMT's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while BBIO trades at $66.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas BBIO's P/E ratio is -17.72. In terms of profitability, APUS's ROE is -0.59%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, APUS is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BBIO's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas KRTX's P/E ratio is -28.09. In terms of profitability, APUS's ROE is -0.59%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, APUS is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check KRTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, BMRN has a market cap of 11.9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while BMRN trades at $61.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas BMRN's P/E ratio is 29.50. In terms of profitability, APUS's ROE is -0.59%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, APUS is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BMRN's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while MDGL trades at $513.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas MDGL's P/E ratio is -40.09. In terms of profitability, APUS's ROE is -0.59%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, APUS is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check MDGL's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, TWST has a market cap of 11.5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while TWST trades at $184.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas TWST's P/E ratio is -82.90. In terms of profitability, APUS's ROE is -0.59%, compared to TWST's ROE of -0.30%. Regarding short-term risk, APUS is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TWST's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while TECH trades at $72.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas TECH's P/E ratio is 37.41. In terms of profitability, APUS's ROE is -0.59%, compared to TECH's ROE of +0.09%. Regarding short-term risk, APUS is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TECH's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas RNAM's P/E ratio is -17.39. In terms of profitability, APUS's ROE is -0.59%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, APUS is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RNAM's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, TXG has a market cap of 10.7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while TXG trades at $84.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas TXG's P/E ratio is -142.56. In terms of profitability, APUS's ROE is -0.59%, compared to TXG's ROE of -0.09%. Regarding short-term risk, APUS is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TXG's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while KRYS trades at $344.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas KRYS's P/E ratio is 43.23. In terms of profitability, APUS's ROE is -0.59%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, APUS is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for APUS.Check KRYS's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, AXSM has a market cap of 10.1B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while AXSM trades at $196.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas AXSM's P/E ratio is -51.18. In terms of profitability, APUS's ROE is -0.59%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, APUS is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check AXSM's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas RXDX's P/E ratio is -56.47. In terms of profitability, APUS's ROE is -0.59%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, APUS is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RXDX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while KYMR trades at $115.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas KYMR's P/E ratio is -36.19. In terms of profitability, APUS's ROE is -0.59%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, APUS is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for APUS.Check KYMR's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ARWR has a market cap of 9.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ARWR trades at $66.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ARWR's P/E ratio is -29.36. In terms of profitability, APUS's ROE is -0.59%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, APUS is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ARWR's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas NUVL's P/E ratio is -21.79. In terms of profitability, APUS's ROE is -0.59%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, APUS is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check NUVL's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CAI has a market cap of 9.1B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CAI trades at $32.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CAI's P/E ratio is 90.67. In terms of profitability, APUS's ROE is -0.59%, compared to CAI's ROE of +0.19%. Regarding short-term risk, APUS is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CAI's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, IBRX has a market cap of 9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while IBRX trades at $8.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas IBRX's P/E ratio is -8.91. In terms of profitability, APUS's ROE is -0.59%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, APUS is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check IBRX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CRNX's P/E ratio is -16.86. In terms of profitability, APUS's ROE is -0.59%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, APUS is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CRNX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while PTGX trades at $137.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas PTGX's P/E ratio is 133.34. In terms of profitability, APUS's ROE is -0.59%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, APUS is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PTGX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, TGTX has a market cap of 8.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while TGTX trades at $57.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas TGTX's P/E ratio is 20.84. In terms of profitability, APUS's ROE is -0.59%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, APUS is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TGTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas IMGN's P/E ratio is -111.55. In terms of profitability, APUS's ROE is -0.59%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, APUS is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check IMGN's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas BPMC's P/E ratio is -51.58. In terms of profitability, APUS's ROE is -0.59%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, APUS is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BPMC's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas APGE's P/E ratio is -31.19. In terms of profitability, APUS's ROE is -0.59%, compared to APGE's ROE of -0.30%. Regarding short-term risk, APUS is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for APUS.Check APGE's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while PCVX trades at $56.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas PCVX's P/E ratio is -7.46. In terms of profitability, APUS's ROE is -0.59%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, APUS is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PCVX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CERE's P/E ratio is -16.47. In terms of profitability, APUS's ROE is -0.59%, compared to CERE's ROE of -0.72%. Regarding short-term risk, APUS is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CERE's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CYTK trades at $65.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CYTK's P/E ratio is -9.10. In terms of profitability, APUS's ROE is -0.59%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, APUS is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CYTK's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, PRAX has a market cap of 7.9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while PRAX trades at $281.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas PRAX's P/E ratio is -21.79. In terms of profitability, APUS's ROE is -0.59%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, APUS is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PRAX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, SYRE has a market cap of 7.6B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while SYRE trades at $87.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas SYRE's P/E ratio is -44.66. In terms of profitability, APUS's ROE is -0.59%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, APUS is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SYRE's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas MTSR's P/E ratio is -23.58. In terms of profitability, APUS's ROE is -0.59%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, APUS is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for APUS.Check MTSR's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, IONS has a market cap of 7.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while IONS trades at $43.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas IONS's P/E ratio is -13.40. In terms of profitability, APUS's ROE is -0.59%, compared to IONS's ROE of -1.11%. Regarding short-term risk, APUS is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for APUS.Check IONS's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, IMVT has a market cap of 7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while IMVT trades at $34.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas IMVT's P/E ratio is -12.06. In terms of profitability, APUS's ROE is -0.59%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, APUS is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check IMVT's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ABVX has a market cap of 7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ABVX trades at $94.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ABVX's P/E ratio is -18.05. In terms of profitability, APUS's ROE is -0.59%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, APUS is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ABVX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas MRUS's P/E ratio is -17.05. In terms of profitability, APUS's ROE is -0.59%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, APUS is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for APUS.Check MRUS's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, BLTE has a market cap of 6.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while BLTE trades at $169.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas BLTE's P/E ratio is -90.61. In terms of profitability, APUS's ROE is -0.59%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, APUS is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for APUS.Check BLTE's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while RYTM trades at $98.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas RYTM's P/E ratio is -31.61. In terms of profitability, APUS's ROE is -0.59%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, APUS is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RYTM's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ACLX's P/E ratio is -28.27. In terms of profitability, APUS's ROE is -0.59%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, APUS is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ACLX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas RETA's P/E ratio is -66.29. In terms of profitability, APUS's ROE is -0.59%, compared to RETA's ROE of +0.47%. Regarding short-term risk, APUS is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RETA's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CNTA's P/E ratio is -22.63. In terms of profitability, APUS's ROE is -0.59%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, APUS is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CNTA's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CGON trades at $68.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CGON's P/E ratio is -25.56. In terms of profitability, APUS's ROE is -0.59%, compared to CGON's ROE of -0.25%. Regarding short-term risk, APUS is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CGON's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while LGND trades at $299.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas LGND's P/E ratio is 32.83. In terms of profitability, APUS's ROE is -0.59%, compared to LGND's ROE of +0.20%. Regarding short-term risk, APUS is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for APUS.Check LGND's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while SRRK trades at $48.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas SRRK's P/E ratio is -14.09. In terms of profitability, APUS's ROE is -0.59%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, APUS is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for APUS.Check SRRK's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, TVTX has a market cap of 5.6B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while TVTX trades at $60.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas TVTX's P/E ratio is -134.71. In terms of profitability, APUS's ROE is -0.59%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, APUS is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TVTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CDTX's P/E ratio is -19.77. In terms of profitability, APUS's ROE is -0.59%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, APUS is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CDTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, APUS's ROE is -0.59%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, APUS is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ABCM's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ISEE's P/E ratio is -22.44. In terms of profitability, APUS's ROE is -0.59%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, APUS is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ISEE's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while MIRM trades at $89.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas MIRM's P/E ratio is -6.14. In terms of profitability, APUS's ROE is -0.59%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, APUS is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for APUS.Check MIRM's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CRSP trades at $55.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CRSP's P/E ratio is -11.70. In terms of profitability, APUS's ROE is -0.59%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, APUS is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CRSP's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while COGT trades at $31.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas COGT's P/E ratio is -14.90. In terms of profitability, APUS's ROE is -0.59%, compared to COGT's ROE of -0.73%. Regarding short-term risk, APUS is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check COGT's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas APLS's P/E ratio is 38.35. In terms of profitability, APUS's ROE is -0.59%, compared to APLS's ROE of +0.40%. Regarding short-term risk, APUS is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for APUS.Check APLS's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, PTCT has a market cap of 5.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while PTCT trades at $62.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas PTCT's P/E ratio is -26.73. In terms of profitability, APUS's ROE is -0.59%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, APUS is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PTCT's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ORKA has a market cap of 5.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ORKA trades at $85.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ORKA's P/E ratio is -44.07. In terms of profitability, APUS's ROE is -0.59%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, APUS is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ORKA's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, DNTH has a market cap of 5.1B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while DNTH trades at $90.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas DNTH's P/E ratio is -21.86. In terms of profitability, APUS's ROE is -0.59%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, APUS is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for APUS.Check DNTH's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ERAS trades at $14.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ERAS's P/E ratio is -15.61. In terms of profitability, APUS's ROE is -0.59%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, APUS is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ERAS's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while DFTX trades at $36.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas DFTX's P/E ratio is N/A. In terms of profitability, APUS's ROE is -0.59%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, APUS is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check DFTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, MANE has a market cap of 4.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while MANE trades at $115.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas MANE's P/E ratio is -36.89. In terms of profitability, APUS's ROE is -0.59%, compared to MANE's ROE of -0.38%. Regarding short-term risk, APUS is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for APUS.Check MANE's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, IOVA has a market cap of 4.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while IOVA trades at $10.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas IOVA's P/E ratio is -14.79. In terms of profitability, APUS's ROE is -0.59%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, APUS is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for APUS.Check IOVA's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas TERN's P/E ratio is -51.41. In terms of profitability, APUS's ROE is -0.59%, compared to TERN's ROE of -0.20%. Regarding short-term risk, APUS is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TERN's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ADPT trades at $29.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ADPT's P/E ratio is -72.12. In terms of profitability, APUS's ROE is -0.59%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, APUS is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ADPT's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas FOLD's P/E ratio is -161.00. In terms of profitability, APUS's ROE is -0.59%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, APUS is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for APUS.Check FOLD's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas AKRO's P/E ratio is -14.57. In terms of profitability, APUS's ROE is -0.59%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, APUS is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for APUS.Check AKRO's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ALPN's P/E ratio is -101.52. In terms of profitability, APUS's ROE is -0.59%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, APUS is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ALPN's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while EWTX trades at $41.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas EWTX's P/E ratio is -22.25. In terms of profitability, APUS's ROE is -0.59%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, APUS is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check EWTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, VKTX has a market cap of 4.3B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while VKTX trades at $36.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas VKTX's P/E ratio is -7.89. In terms of profitability, APUS's ROE is -0.59%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, APUS is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check VKTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas OPT's P/E ratio is -1.52. In terms of profitability, APUS's ROE is -0.59%, compared to OPT's ROE of +1.18%. Regarding short-term risk, APUS is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for APUS.Check OPT's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas PRTC's P/E ratio is -3.78. In terms of profitability, APUS's ROE is -0.59%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, APUS is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PRTC's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas MRTX's P/E ratio is -4.82. In terms of profitability, APUS's ROE is -0.59%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, APUS is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check MRTX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while TNGX trades at $24.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas TNGX's P/E ratio is -29.67. In terms of profitability, APUS's ROE is -0.59%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, APUS is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TNGX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, RLAY has a market cap of 3.9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while RLAY trades at $17.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas RLAY's P/E ratio is -11.29. In terms of profitability, APUS's ROE is -0.59%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, APUS is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RLAY's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CELC trades at $79.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CELC's P/E ratio is -18.46. In terms of profitability, APUS's ROE is -0.59%, compared to CELC's ROE of -3.51%. Regarding short-term risk, APUS is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CELC's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ABCL trades at $12.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ABCL's P/E ratio is -23.43. In terms of profitability, APUS's ROE is -0.59%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, APUS is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ABCL's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CPRX's P/E ratio is 17.49. In terms of profitability, APUS's ROE is -0.59%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, APUS is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CPRX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while TLX trades at $11.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas TLX's P/E ratio is 118.06. In terms of profitability, APUS's ROE is -0.59%, compared to TLX's ROE of +0.07%. Regarding short-term risk, APUS is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for APUS.Check TLX's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while ACAD trades at $22.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas ACAD's P/E ratio is 9.99. In terms of profitability, APUS's ROE is -0.59%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, APUS is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for APUS.Check ACAD's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, PBLS has a market cap of 3.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while PBLS trades at $32.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas PBLS's P/E ratio is -17.27. In terms of profitability, APUS's ROE is -0.59%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, APUS is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for APUS.Check PBLS's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas RYZB's P/E ratio is -57.86. In terms of profitability, APUS's ROE is -0.59%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, APUS is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for APUS.Check RYZB's competition here

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, APUS stands at 7.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, APUS is priced at $4.92 on the AMEX, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

APUS currently has a P/E ratio of -0.14, whereas CBAY's P/E ratio is -32.81. In terms of profitability, APUS's ROE is -0.59%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, APUS is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for APUS.Check CBAY's competition here